Phase II Trial of Trimetrexate for Unresectable or Metastatic Non-small Cell Bronchogenic Carcinoma
Overview
Overview
Journal
Invest New Drugs
Publisher
Springer
Specialty
Oncology
Date
1992 Nov 1
PMID
1336771
Citations
1
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.
Citing Articles
Walling J Invest New Drugs. 2005; 24(1):37-77.
PMID: 16380836 DOI: 10.1007/s10637-005-4541-1.
References
1.
Jackson R, Leopold W, Hamelehle K, FRY D
. Preclinical studies with trimetrexate: a review of conclusions and unanswered questions. Semin Oncol. 1988; 15(2 Suppl 2):1-7.
View
2.
Kris M, DAcquisto R, Gralla R, Burke M, Marks L, Fanucchi M
. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. Am J Clin Oncol. 1989; 12(1):24-6.
DOI: 10.1097/00000421-198902000-00006.
View
3.
Fanucchi M, Walsh T, Fleisher M, Lokos G, Williams L, Cassidy C
. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res. 1987; 47(12):3303-8.
View
4.
Lin J, Cashmore A, Baker M, Dreyer R, Ernstoff M, Marsh J
. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Res. 1987; 47(2):609-16.
View
5.
Maroun J
. Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer. Semin Oncol. 1988; 15(2 Suppl 2):17-21.
View